GSK’s Q4 2015 results highlighted significantly improved performance from the products incorporating Skyepharma’s dry powder inhalation formulation technologies. The Ellipta® range (Breo®/Relvar®, Anoro® and Incruse®) continued to post growth with combined sales in Q4 increasing 53% from Q3, generating full year sales of £350m (ahead of our £335m estimate). We expect the positive momentum to continue going forward although we make no changes to our forecasts at this stage. We believe Skyepharma ....
04 Feb 2016
GSK Q4 2015 results highlight Ellipta® sales ahead of expectations
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
GSK Q4 2015 results highlight Ellipta® sales ahead of expectations
SkyePharma (SKP:LON) | 0 0 0.0% | Mkt Cap: 470.3m
- Published:
04 Feb 2016 -
Author:
Sheena Berry -
Pages:
3
GSK’s Q4 2015 results highlighted significantly improved performance from the products incorporating Skyepharma’s dry powder inhalation formulation technologies. The Ellipta® range (Breo®/Relvar®, Anoro® and Incruse®) continued to post growth with combined sales in Q4 increasing 53% from Q3, generating full year sales of £350m (ahead of our £335m estimate). We expect the positive momentum to continue going forward although we make no changes to our forecasts at this stage. We believe Skyepharma ....